



US008673927B2

(12) **United States Patent**  
**Dugi et al.**

(10) **Patent No.:** **US 8,673,927 B2**  
(45) **Date of Patent:** **\*Mar. 18, 2014**

- (54) **USES OF DPP-IV INHIBITORS**
- (75) Inventors: **Klaus Dugi**, Dresden (DE); **Frank Himmelsbach**, Mittelbiberach (DE); **Michael Mark**, Biberach (DE)
- (73) Assignee: **Boehringer Ingelheim International GmbH**, Ingelheim am Rhein (DE)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 111 days.  
This patent is subject to a terminal disclaimer.
- (21) Appl. No.: **12/946,193**
- (22) Filed: **Nov. 15, 2010**
- (65) **Prior Publication Data**  
US 2011/0065731 A1 Mar. 17, 2011

**Related U.S. Application Data**

- (63) Continuation of application No. 11/744,703, filed on May 4, 2007, now Pat. No. 8,232,281.

**(30) Foreign Application Priority Data**

May 4, 2006 (EP) ..... 06009203

**(51) Int. Cl.**

**A61K 31/52** (2006.01)  
**A61K 31/155** (2006.01)

**(52) U.S. Cl.**

USPC ..... **514/263.21**; 514/635; 514/868

**(58) Field of Classification Search**

USPC ..... 514/263.21, 635, 866  
See application file for complete search history.

**(56) References Cited**

## U.S. PATENT DOCUMENTS

2,056,046 A 9/1936 Fourneau  
2,375,138 A 5/1945 Victors  
2,629,736 A 2/1953 Krimmel  
2,730,544 A 1/1956 Sahyun  
2,750,387 A 6/1956 Krimmel  
2,928,833 A 3/1960 Leake et al.  
3,174,901 A 3/1965 Sterne  
3,236,891 A 2/1966 Seemuller  
3,454,635 A 7/1969 Muth  
3,673,241 A 6/1972 Marxer  
3,925,357 A 12/1975 Okada et al.  
4,005,208 A 1/1977 Bender et al.  
4,061,753 A 12/1977 Bodor et al.  
4,599,338 A 7/1986 Regnier et al.  
4,639,436 A 1/1987 Junge et al.  
4,687,777 A 8/1987 Meguro et al.  
4,816,455 A 3/1989 Schickaneder et al.  
4,873,330 A 10/1989 Lindholm  
4,968,672 A 11/1990 Jacobson et al.  
5,041,448 A 8/1991 Janssens et al.  
5,051,517 A 9/1991 Findeisen et al.  
5,084,460 A 1/1992 Munson, Jr. et al.

5,234,897 A 8/1993 Findeisen et al.  
5,258,380 A 11/1993 Janssens et al.  
5,266,555 A 11/1993 Findeisen et al.  
5,273,995 A 12/1993 Roth  
5,284,967 A 2/1994 Macher  
5,300,298 A 4/1994 LaNoue  
5,329,025 A 7/1994 Wong et al.  
5,332,744 A 7/1994 Chakravarty et al.  
5,389,642 A 2/1995 Dorsch et al.  
5,399,578 A 3/1995 Buhlmayer et al.  
5,407,929 A 4/1995 Takahashi et al.  
5,470,579 A 11/1995 Bonte et al.  
5,591,762 A 1/1997 Hael et al.  
5,594,003 A 1/1997 Hael et al.  
5,602,127 A 2/1997 Hael et al.  
5,614,519 A 3/1997 Hael et al.  
5,719,279 A 2/1998 Kufner-Muhl et al.  
5,728,849 A 3/1998 Bouchard et al.  
5,753,635 A 5/1998 Buckman et al.  
5,830,908 A 11/1998 Grunenberg et al.  
5,958,951 A 9/1999 Ahrndt et al.  
5,965,555 A 10/1999 Gebert et al.  
5,965,592 A 10/1999 Buhlmayer et al.  
6,011,049 A 1/2000 Whitcomb  
6,107,302 A 8/2000 Carter et al.  
6,166,063 A 12/2000 Villhauer

(Continued)

## FOREIGN PATENT DOCUMENTS

AU 2003280680 A1 6/2004  
AU 2009224546 A1 9/2009

(Continued)

## OTHER PUBLICATIONS

Bastin, R.J. et al., "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities". Organic Process Research and Development, 2000, vol. 4, p. 427-435.

Chemical Abstract: No. 211513-37-0—Dalcetrapib. "Propanethioic acid, 2-methyl-,S-(2-[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl]ester". Formula: C23 H35 N O2 S. American Chemical Society, Sep. 20, 1998.

Chemical Abstract: No. 875446-37-0—Anacetrapib. "2-Oxazolidinone, 5-[3,5-bis(trifluoromethyl)phenyl]-3[[4'fluoro-2'-methoxy-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-,(4S,5R)-". Formula: C30 H25 F10 N O3. American Chemical Society, Feb. 28, 2006.

(Continued)

*Primary Examiner* — Kevin E Weddington

(74) *Attorney, Agent, or Firm* — Michael P. Morris; David L. Kershner

**(57) ABSTRACT**

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,248,758	B1	6/2001	Klokkers et al.	2004/0097510	A1	5/2004	Himmelsbach et al.
6,303,661	B1	10/2001	Demuth et al.	2004/0116328	A1	6/2004	Yoshikawa et al.
6,342,601	B1	1/2002	Bantick et al.	2004/0122048	A1	6/2004	Benjamin et al.
6,372,940	B1	4/2002	Cavazza	2004/0122228	A1	6/2004	Maier et al.
6,548,481	B1	4/2003	Demuth et al.	2004/0126358	A1	7/2004	Warne et al.
6,579,868	B1	6/2003	Asano et al.	2004/0138214	A1	7/2004	Himmelsbach et al.
6,727,261	B2	4/2004	Gobbi et al.	2004/0138215	A1	7/2004	Eckhardt et al.
6,784,195	B2	8/2004	Hale et al.	2004/0166125	A1	8/2004	Himmelsbach et al.
6,821,978	B2	11/2004	Chackalamannil et al.	2004/0180925	A1	9/2004	Matsuno et al.
6,869,947	B2	3/2005	Kanstrup et al.	2004/0259903	A1	12/2004	Boehringer et al.
6,995,183	B2	2/2006	Hamann et al.	2005/0020574	A1	1/2005	Hauel et al.
7,060,722	B2	6/2006	Kitajima et al.	2005/0026921	A1	2/2005	Eckhardt et al.
7,074,794	B2	7/2006	Kitajima et al.	2005/0032804	A1	2/2005	Cypes et al.
7,074,798	B2	7/2006	Yoshikawa et al.	2005/0070562	A1	3/2005	Jones et al.
7,074,923	B2	7/2006	Dahanukar et al.	2005/0070594	A1	3/2005	Kauschke et al.
7,109,192	B2	9/2006	Hauel et al.	2005/0130985	A1	6/2005	Himmelsbach et al.
7,179,809	B2	2/2007	Eckhardt et al.	2005/0143377	A1	6/2005	Himmelsbach et al.
7,183,280	B2	2/2007	Himmelsbach et al.	2005/0171093	A1	8/2005	Eckhardt et al.
7,192,952	B2	3/2007	Kanstrup et al.	2005/0187227	A1	8/2005	Himmelsbach et al.
7,217,711	B2	5/2007	Eckhardt et al.	2005/0203095	A1	9/2005	Eckhardt et al.
7,235,538	B2	6/2007	Kanstrup et al.	2005/0234108	A1	10/2005	Himmelsbach et al.
7,291,642	B2	11/2007	Kauffmann-Hefner et al.	2005/0234235	A1	10/2005	Eckhardt et al.
7,361,687	B2	4/2008	Barth et al.	2005/0239778	A1	10/2005	Konetzki et al.
7,393,847	B2	7/2008	Eckhardt et al.	2005/0256310	A1	11/2005	Hulin et al.
7,407,955	B2	8/2008	Himmelsbach et al.	2005/0261271	A1	11/2005	Feng et al.
7,432,262	B2	10/2008	Eckhardt et al.	2005/0261352	A1	11/2005	Eckhardt
7,439,370	B2	10/2008	Eckhardt	2005/0266080	A1	12/2005	Desai et al.
7,470,716	B2	12/2008	Eckhardt et al.	2005/0276794	A1	12/2005	Papas et al.
7,476,671	B2	1/2009	Eckhardt et al.	2006/0004074	A1	1/2006	Eckhardt et al.
7,482,337	B2	1/2009	Himmelsbach et al.	2006/0039974	A1	2/2006	Akiyama et al.
7,495,002	B2	2/2009	Langkopf et al.	2006/0047125	A1	3/2006	Leonardi et al.
7,495,003	B2	2/2009	Eckhardt et al.	2006/0058323	A1	3/2006	Eckhardt et al.
7,495,005	B2	2/2009	Himmelsbach et al.	2006/0063787	A1	3/2006	Yoshikawa et al.
7,501,426	B2	3/2009	Himmelsbach et al.	2006/0074058	A1	4/2006	Holmes et al.
7,550,455	B2	6/2009	Himmelsbach et al.	2006/0079541	A1	4/2006	Langkopf et al.
7,560,450	B2	7/2009	Eckhardt et al.	2006/0094722	A1	5/2006	Yasuda et al.
7,566,707	B2	7/2009	Eckhardt et al.	2006/0100199	A1	5/2006	Yoshikawa et al.
7,569,574	B2	8/2009	Maier et al.	2006/0106035	A1	5/2006	Hendrix et al.
7,579,449	B2	8/2009	Eckhardt et al.	2006/0111372	A1	5/2006	Hendrix et al.
7,610,153	B2	10/2009	Carter, Jr. et al.	2006/0111379	A1	5/2006	Guillemont et al.
7,645,763	B2	1/2010	Himmelsbach et al.	2006/0142310	A1	6/2006	Pfrenkle et al.
7,718,666	B2	5/2010	Boehringer et al.	2006/0154866	A1	7/2006	Chu et al.
7,799,782	B2	9/2010	Munson et al.	2006/0159746	A1	7/2006	Troup et al.
7,820,815	B2	10/2010	Pfrenkle et al.	2006/0173056	A1	8/2006	Kitajima et al.
7,838,529	B2	11/2010	Himmelsbach et al.	2006/0205711	A1	9/2006	Himmelsbach et al.
8,039,477	B2	10/2011	Hendrix et al.	2006/0205943	A1	9/2006	Dahanukar et al.
8,071,583	B2	12/2011	Himmelsbach	2006/0247226	A1	11/2006	Himmelsbach et al.
8,106,060	B2	1/2012	Pfrenkle et al.	2006/0270668	A1	11/2006	Chew et al.
8,119,648	B2*	2/2012	Himmelsbach et al. . . . . 514/263.21	2006/0270701	A1	11/2006	Kroth et al.
8,158,633	B2	4/2012	Hendrix et al.	2007/0027168	A1	2/2007	Pfrenkle et al.
8,178,541	B2*	5/2012	Himmelsbach et al. . . . . 514/263.21	2007/0060530	A1	3/2007	Christopher et al.
8,232,281	B2*	7/2012	Dugi et al. . . . . 514/263.21	2007/0072803	A1	3/2007	Chu et al.
2001/0020006	A1	9/2001	Demuth et al.	2007/0072810	A1	3/2007	Asakawa
2001/0051646	A1	12/2001	Demuth et al.	2007/0088038	A1	4/2007	Eckhardt et al.
2002/0019411	A1	2/2002	Robl et al.	2007/0093659	A1	4/2007	Bonfanti et al.
2002/0137903	A1	9/2002	Ellsworth et al.	2007/0142383	A1	6/2007	Eckhardt et al.
2002/0161001	A1	10/2002	Kanstrup et al.	2007/0185091	A1	8/2007	Himmelsbach et al.
2002/0169174	A1	11/2002	Chackalamannil et al.	2007/0196472	A1	8/2007	Kiel et al.
2002/0198205	A1	12/2002	Himmelsbach et al.	2007/0219178	A1	9/2007	Muramoto
2003/0078269	A1	4/2003	Pearson et al.	2007/0259900	A1	11/2007	Sieger et al.
2003/0100563	A1	5/2003	Edmondson et al.	2007/0259925	A1	11/2007	Boehringer et al.
2003/0105077	A1	6/2003	Kanstrup et al.	2007/0259927	A1	11/2007	Suzuki et al.
2003/0114390	A1	6/2003	Washburn et al.	2007/0281940	A1	12/2007	Dugi et al.
2003/0149071	A1	8/2003	Gobbi et al.	2007/0299076	A1	12/2007	Piotrowski et al.
2003/0166578	A1	9/2003	Arch et al.	2008/0039427	A1	2/2008	Ray et al.
2003/0199528	A1	10/2003	Kanstrup et al.	2008/0107731	A1	5/2008	Kohlrausch et al.
2003/0224043	A1	12/2003	Appel et al.	2008/0108816	A1	5/2008	Zutter
2003/0232987	A1	12/2003	Dahanukar et al.	2008/0249089	A1	10/2008	Himmelsbach et al.
2003/0236272	A1	12/2003	Carr	2008/0255159	A1	10/2008	Himmelsbach et al.
2004/0023981	A1	2/2004	Ren et al.	2008/0312243	A1	12/2008	Eckhardt et al.
2004/0034014	A1	2/2004	Kanstrup et al.	2008/0318922	A1	12/2008	Nakahira et al.
2004/0063725	A1	4/2004	Barth et al.	2009/0023920	A1	1/2009	Eckhardt
2004/0077645	A1	4/2004	Himmelsbach et al.	2009/0088408	A1	4/2009	Meade et al.
				2009/0088569	A1	4/2009	Eckhardt et al.
				2009/0093457	A1	4/2009	Himmelsbach et al.
				2009/0131432	A1	5/2009	Himmelsbach et al.
				2009/0136596	A1	5/2009	Munson et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2009/0186086 A1 7/2009 Shankar et al.  
 2009/0192314 A1 7/2009 Pfrenkle et al.  
 2009/0297470 A1 12/2009 Franz  
 2009/0301105 A1 12/2009 Loerting  
 2009/0325926 A1 12/2009 Himmelsbach  
 2010/0074950 A1 3/2010 Sesha  
 2010/0092551 A1 4/2010 Nakamura et al.  
 2010/0173916 A1 7/2010 Himmelsbach et al.  
 2010/0183531 A1 7/2010 Johncock et al.  
 2010/0204250 A1 8/2010 Himmelsbach et al.  
 2011/0009391 A1 1/2011 Braun et al.  
 2011/0046076 A1 2/2011 Eickelmann et al.  
 2011/0065731 A1 3/2011 Dugi et al.  
 2011/0092510 A1 4/2011 Klein et al.  
 2011/0098240 A1 4/2011 Dugi et al.  
 2011/0112069 A1 5/2011 Himmelsbach et al.  
 2011/0144083 A1 6/2011 Himmelsbach et al.  
 2011/0144095 A1 6/2011 Himmelsbach et al.  
 2011/0190322 A1 8/2011 Klein et al.  
 2011/0195917 A1 8/2011 Dugi et al.  
 2011/0206766 A1 8/2011 Friedl et al.  
 2011/0263493 A1 10/2011 Dugi et al.  
 2011/0263617 A1 10/2011 Mark et al.  
 2011/0275561 A1 11/2011 Graefe-Mody et al.  
 2011/0301182 A1 12/2011 Dugi  
 2012/0003313 A1 1/2012 Kohlrausch et al.  
 2012/0035158 A1 2/2012 Himmelsbach et al.  
 2012/0040982 A1 2/2012 Himmelsbach et al.  
 2012/0053173 A1 3/2012 Banno et al.  
 2012/0094894 A1 4/2012 Graefe-Mody et al.  
 2012/0107398 A1 5/2012 Schneider et al.  
 2012/0121530 A1 5/2012 Klein et al.  
 2012/0122776 A1 5/2012 Graefe-Mody et al.  
 2012/0129874 A1 5/2012 Sieger et al.  
 2012/0142712 A1 6/2012 Pfrenkle et al.  
 2012/0165251 A1 6/2012 Klein et al.  
 2012/0208831 A1 8/2012 Himmelsbach et al.  
 2012/0219622 A1 8/2012 Kohlrausch et al.  
 2012/0219623 A1 8/2012 Meinicke  
 2012/0252782 A1 10/2012 Himmelsbach et al.  
 2012/0252783 A1 10/2012 Himmelsbach et al.  
 2012/0296091 A1 11/2012 Sieger et al.  
 2013/0172244 A1 7/2013 Klein et al.  
 2013/0184204 A1 7/2013 Pfrenkle et al.  
 2013/0196898 A1 8/2013 Dugi et al.

FOREIGN PATENT DOCUMENTS

CA 1123437 A1 5/1982  
 CA 2136288 A1 5/1995  
 CA 2418656 A1 2/2002  
 CA 2496249 A1 3/2004  
 CA 2496325 A1 3/2004  
 CA 2498423 A1 4/2004  
 CA 2505389 A1 5/2004  
 CA 2508233 A1 6/2004  
 CA 2529729 A1 12/2004  
 CA 2543074 A1 6/2005  
 CA 2555050 A1 9/2005  
 CA 2556064 A1 9/2005  
 CA 2558067 A1 10/2005  
 CA 2561210 A1 10/2005  
 CA 2562859 A1 11/2005  
 CA 2576294 A1 3/2006  
 CA 2590912 A1 6/2006  
 CA 2651019 A1 11/2007  
 CA 2651089 A1 11/2007  
 CN 101234105 A 8/2008  
 DE 2205815 A1 8/1973  
 DE 2758025 A1 7/1979  
 DE 10109021 A1 9/2002  
 DE 10117803 A1 10/2002

DE 102004024454 A1 12/2005  
 DE 102004044221 A1 3/2006  
 DE 102004054054 A1 5/2006  
 EP 0023032 A1 1/1981  
 EP 0149578 A2 7/1985  
 EP 0223403 A2 5/1987  
 EP 0237608 A1 9/1987  
 EP 0248634 A2 12/1987  
 EP 0389282 A2 9/1990  
 EP 0399285 A1 11/1990  
 EP 0400974 A2 12/1990  
 EP 409281 A1 1/1991  
 EP 0412358 A1 2/1991  
 EP 443983 A1 8/1991  
 EP 0524482 A1 1/1993  
 EP 0657454 A1 6/1995  
 EP 0775704 A1 5/1997  
 EP 0950658 A1 10/1999  
 EP 1054012 A1 11/2000  
 EP 1066265 A1 1/2001  
 EP 1333033 8/2003  
 EP 1338595 A2 8/2003  
 EP 1406873 A2 4/2004  
 EP 1500403 A1 1/2005  
 EP 1514552 A1 3/2005  
 EP 1537880 A1 6/2005  
 EP 1557165 A1 7/2005  
 EP 1586571 A1 10/2005  
 EP 1743655 A1 1/2007  
 EP 1760076 3/2007  
 EP 1829877 A1 9/2007  
 EP 1852108 A1 11/2007  
 EP 2143443 A1 1/2010  
 ES 385302 A1 4/1973  
 ES 2256797 T3 7/2006  
 ES 2263057 T3 12/2006  
 FR 2707641 A1 1/1995  
 GB 2084580 A 4/1982  
 HU 9003243 5/1990  
 HU 9902308 A2 7/2000  
 JP S374895 A 6/1962  
 JP 770120 3/1995  
 JP 2000502684 A 3/2000  
 JP 2001213770 A 8/2001  
 JP 2003300977 A 10/2003  
 JP 2006045156 A 2/2006  
 JP 2010053576 A 3/2010  
 KR 20070111099 A 11/2007  
 WO 9107945 A1 6/1991  
 WO 9205175 A1 4/1992  
 WO 9219227 A2 11/1992  
 WO 9402150 A1 2/1994  
 WO 9403456 A1 2/1994  
 WO 9532178 A1 11/1995  
 WO 9609045 A1 3/1996  
 WO 9636638 A1 11/1996  
 WO 9723447 A1 7/1997  
 WO 9723473 A1 7/1997  
 WO 9746526 A1 12/1997  
 WO 9807725 2/1998  
 WO 9811893 A1 3/1998  
 WO 9818770 A1 5/1998  
 WO 9822464 A1 5/1998  
 WO 9828007 A1 7/1998  
 WO 9840069 A2 9/1998  
 WO 9856406 A1 12/1998  
 WO 9929695 A1 6/1999  
 WO 9950248 A1 10/1999  
 WO 0073307 A2 12/2000  
 WO 0107441 A1 2/2001  
 WO 0140180 A2 6/2001  
 WO 0152825 A2 7/2001  
 WO 0152852 A1 7/2001  
 WO 0168646 A1 9/2001  
 WO 0177110 A1 10/2001  
 WO 0197808 A1 12/2001  
 WO 0202560 A2 1/2002

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO 02053516 A2 7/2002  
 WO 02068420 A1 9/2002  
 WO 03000241 A2 1/2003  
 WO 03002531 A2 1/2003  
 WO 03004496 A1 1/2003  
 WO 03024965 A2 3/2003  
 WO 03037327 A1 5/2003  
 WO 03055881 A1 7/2003  
 WO 03057200 A2 7/2003  
 WO 03064454 A1 8/2003  
 WO 03088900 A2 10/2003  
 WO 03099279 A1 12/2003  
 WO 03099836 A1 12/2003  
 WO 03104229 A1 12/2003  
 WO 03106428 A1 12/2003  
 WO 2004002924 A1 1/2004  
 WO 2004011416 A1 2/2004  
 WO 2004018467 A2 3/2004  
 WO 2004018468 A2 3/2004  
 WO 2004018469 A1 3/2004  
 WO 2004028524 A1 4/2004  
 WO 2004033455 A1 4/2004  
 WO 2004035575 A1 4/2004  
 WO 2004041820 A1 5/2004  
 WO 2004046148 A1 6/2004  
 WO 2004048379 A1 6/2004  
 WO 2004050658 A1 6/2004  
 WO 2004052362 A1 6/2004  
 WO 2004058233 A1 7/2004  
 WO 2004062689 A1 7/2004  
 WO 2004065380 A 8/2004  
 WO 2004081006 A1 9/2004  
 WO 2004082402 A1 9/2004  
 WO 2004096806 A1 11/2004  
 WO 2004096811 A1 11/2004  
 WO 2004106279 A2 12/2004  
 WO 2004108730 A1 12/2004  
 WO 2004111051 A1 12/2004  
 WO 2005000846 A1 1/2005  
 WO 2005000848 A1 1/2005  
 WO 2005007647 A1 1/2005  
 WO 2005012288 A1 2/2005  
 WO 2005023179 A2 3/2005  
 WO 2005049022 A2 6/2005  
 WO 2005051950 A1 6/2005  
 WO 2005058901 A1 6/2005  
 WO 2005061489 A1 7/2005  
 WO 2005063750 A1 7/2005  
 WO 2005082906 A1 9/2005  
 WO 2005085246 A1 9/2005  
 WO 2005092870 A1 10/2005  
 WO 2005092877 A1 10/2005  
 WO 2005095343 A1 10/2005  
 WO 2005097798 A 10/2005  
 WO 2005116000 A1 12/2005  
 WO 2005116014 A1 12/2005  
 WO 2005117861 A1 12/2005  
 WO 2005117948 A1 12/2005  
 WO 2006005613 A1 1/2006  
 WO 2006027204 A1 3/2006  
 WO 2006029769 A1 3/2006  
 WO 2006036664 A1 4/2006  
 WO 2006040625 A1 4/2006  
 WO 2006047248 A1 5/2006  
 WO 2006048209 A1 5/2006  
 WO 2006048427 A1 5/2006  
 WO 2006068163 A1 6/2006  
 WO 2006071078 A1 7/2006  
 WO 2006076231 A2 7/2006  
 WO 2006083491 A2 8/2006  
 WO 2006135693 A2 12/2006  
 WO 2006137085 A1 12/2006  
 WO 2007007173 A2 1/2007

WO 2007017423 A1 2/2007  
 WO 2007033350 A1 3/2007  
 WO 2007035355 A2 3/2007  
 WO 2007035665 A1 3/2007  
 WO 2007041053 A2 4/2007  
 WO 2007071738 6/2007  
 WO 2007072083 A1 6/2007  
 WO 2007078726 A2 7/2007  
 WO 2007093610 A1 8/2007  
 WO 2007099345 A1 9/2007  
 WO 2007120702 A2 10/2007  
 WO 2007120936 A2 10/2007  
 WO 2007128721 A 11/2007  
 WO 2007128724 A1 11/2007  
 WO 2007128761 A2 11/2007  
 WO 2007135196 A2 11/2007  
 WO 2007137107 A2 11/2007  
 WO 2007147185 A1 12/2007  
 WO 2007148185 A2 12/2007  
 WO 2007149797 A2 12/2007  
 WO 2008005569 A2 1/2008  
 WO 2008005576 A1 1/2008  
 WO 2008017670 2/2008  
 WO 2008022267 A2 2/2008  
 WO 2008055870 A1 5/2008  
 WO 2008055940 A2 5/2008  
 WO 2008070692 A2 6/2008  
 WO 2008081205 A1 7/2008  
 WO 2008083238 A2 7/2008  
 WO 2008087198 A1 7/2008  
 WO 2008093878 A1 8/2008  
 WO 2008093882 A1 8/2008  
 WO 2008113000 A1 9/2008  
 WO 2008131149 A2 10/2008  
 WO 2009011451 A 1/2009  
 WO 2009022007 A1 2/2009  
 WO 2009022008 A1 2/2009  
 WO 2009022010 A1 2/2009  
 WO 2009024542 A2 2/2009  
 WO 2009063072 A2 5/2009  
 WO 2009064399 A1 5/2009  
 WO 2009099734 A1 8/2009  
 WO 2009112691 A2 9/2009  
 WO 2009121945 A2 10/2009  
 WO 2009123992 A1 10/2009  
 WO 2009147125 A1 12/2009  
 WO 2010015664 A1 2/2010  
 WO 2010018217 A2 2/2010  
 WO 2010029089 A2 3/2010  
 WO 2010043688 A1 4/2010  
 WO 2010045656 A2 4/2010  
 WO 2010072776 A1 7/2010  
 WO 2010079197 A1 7/2010  
 WO 2010086411 A1 8/2010  
 WO 2010092125 A1 8/2010  
 WO 2010096384 A2 8/2010  
 WO 20100092163 A2 8/2010  
 WO 2010106457 A2 9/2010  
 WO 2010147768 A1 12/2010  
 WO 2011039367 A2 4/2011  
 WO 2011064352 A1 6/2011  
 WO 2011113947 A1 9/2011  
 WO 2011138380 A1 11/2011  
 WO 2011138421 A1 11/2011  
 WO 2011161161 A1 12/2011  
 WO 2012065993 A1 5/2012  
 WO 2013103629 A1 7/2013

OTHER PUBLICATIONS

Clinical Trials: NCT00954447, View on Jun. 14, 2010. "Efficacy and Safety of Linagliptin in Combination with Insulin in Patients with Type 2 Diabetes". <[http://clinicaltrials.gov/archive/NCT00954447/2010\\_06\\_14](http://clinicaltrials.gov/archive/NCT00954447/2010_06_14)>.  
 Demuth, H-U. et al., "Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors". *Biochimica et Biophysica Acta*, vol. 1751(1), 2005, p. 33-44.  
 Gallwitz, B. "Sitagliptin with Metformin: Profile of a Combination

(56)

## References Cited

## OTHER PUBLICATIONS

- Graefe-Mody, et al; Evaluation of the Potential for Steady-State Pharmacokinetic and Pharmacodynamic Interactions Between the DPP-4 Inhibitor Linagliptin and Metformin in Healthy Subjects; *Currents Medical Research and Opinion* (2009) vol. 25, No. 8 pp. 1963-1972.
- He, Y. L. et al., "Bioequivalence of Vildagliptin/Metformin Combination Tablets and Coadministration of Vildagliptin and Metformin as Free Combination in Healthy Subjects". *J. Clinical Pharmacology*, 2007, vol. 47, No. 9, Abstracts of the 36th Annual Meeting of the American College of Clinical Pharmacology, San Francisco, CA, Abstract 116, p. 1210.
- Hunziker, D. et al., "Inhibitors of DPP IV—recent advances and structural views", *Current Topics in Medicinal Chemistry*, 2005, vol. 5 issue 16, pp. 1623-1637.
- Knorr, M. et al., "Comparison of Direct and Indirect Antioxidant Effects of Linagliptin (BI 1356, Oндero) with other Gliptins—Evidence for Anti-Inflammatory Properties of Linagliptin". *Free Radical Biology and medicine*, Elsevier Science, U.S. vol. 49, Oct. 23, 2010, p. S197.
- Levien, T.L. et al., "New drugs in development for the treatment of diabetes", *Diabetes Spectrum*, American Diabetes Association, US, vol. 22, No. 2, Jan. 1, 2009, pp. 92-106.
- Meece, J. "When Oral Agents Fail: Optimizing Insulin Therapy in the Older Adult". *Consultant Pharmacist*, The Society, Arlington, VA US. vol. 24, No. Suppl B, Jun. 1, 2009, p. 11-17.
- Rosenstock, J. et al., "Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia". *Diabetes, Obesity and Metabolism*, Dec. 2009, vol. 11, No. 12, p. 1145-1152.
- Sune Negre, J. M. "New Galenic Contributions to Administration Forms". *Continued Training for Hospital Pharmacists 3.2*. [retrieved on Feb. 23, 2011]. Retrieved from the internet <<http://www.ub.es/legmh/capitols/sunyenegre.pdf>>.
- Thomas, L., "Chronic treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356(9R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione) Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models" *The Journal of Pharmacology and Experimental Therapeutics*, Feb. 2009, vol. 328, No. 2, pp. 556-563.
- Conarello, S.L. et al; "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance," *PNAS* 2003; 100:6825-6830; originally published online May 14, 2003; information current as of Dec. 2006. [www.pnas.org/cgi/content/full/100/11/6825](http://www.pnas.org/cgi/content/full/100/11/6825).
- European Search Report for EP 08 15 9141 mailed Apr. 6, 2009 (European counterpart of U.S. Appl. No. 12/143,128).
- Uhlir-Laske, B. et al., "Linagliptin, a Potent and Selective DPP-4 Inhibitor, is Safe and Efficacious in Patients with Inadequately Controlled Type 2 Diabetes Despite Metformin Therapy". 535-P *Clinical Therapeutics/New Technology—Pharmacologic Treatment of Diabetes or Its Complications*, Posters, vol. 58, Jun. 5, 2009, p. A143. Abstract in English for German DE2205815, 1972. Abstract in English for German EP0023032, 1981. Abstract in English, for KR20070111099, Nov. 11, 2007.
- Augeri, D.J. "Discovery and Preclinical Profile of Saxagliptin (GMB-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes". *Journal Med. Chem*, 2005, vol. 48, No. 15, p. 5025-5037.
- Augustyns, K. et al., "The Unique Properties of Dipeptidyl-peptidase IV (DPP IV/CD 26) and the Therapeutic Potential of DPP-IV Inhibitors." *Current Medicinal Chemistry*, vol. 6, No. 4, 1999, pp. 311-327.
- Aulinger, B.A. et al., "Ex-4 and the DPP-IV Inhibitor Vildagliptin have Additive Effects to Suppress Food Intake in Rodents". Abstract No. 1545-P, 2008.
- Balaban, Y.H. et al., "Dipeptidyl peptidase IV (DDP IV) in NASH Balkan, B. et al, "Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats". *Diabetologia*, 1999, 42, p. 1324-1331.
- Beljean-Leymarie et al., *Hydrazines et hydrazones heterocycliques. IV. Syntheses de derives de l'hydrazine dans la serie des imidazo[4,5-d]pyridazinones-4*, *Can. J. Chem.*, vol. 61, No. 11, 1983, pp. 2563-2566.
- Bollag, R.J. et al; "Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors," *Endocrinology*, vol. 141, No. 3, 2000, pp. 1228-1235.
- Brazg, R. et al; "Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes." *Diabetes, Obesity and Metabolism*, Mar. 2007, vol. 9, No. 2, pp. 18-193.
- Brittain, H.G., "Methods for the Characterization of Polymorphs: X-Ray Powder Diffraction," *Polymorphism in Pharmaceutical Solids*, 1999, p. 235-238.
- Busso et al., "Circulating CD26 is Negatively Associated with Inflammation in Human and Experimental Arthritis," *Am. J. Path.*, vol. 166, No. 2, Feb. 2005, pp. 433-442.
- Caira, M.R., "Crystalline polymorphism of organic compounds" *Topics in Current Chemistry*, Springer, Berlin, vol. 198, 1998, p. 163-208.
- Chemical Abstract. EP412358, 1991:185517, Findeisen.
- Chemical Abstract: FR2707641, 1995:543545, Dodey.
- Chemical Abstracts Accession No. 106:95577 Romanenko et al., "Synthesis and Biological Activity of 3-Methyl, 7- or 8-alkyl-7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," *Zaporozh. Med. Institute* (1986).
- Chemical Abstracts Accession No. 1987:95577: Abstract of Romanenko et al., "Synthesis and biological activity of 3-methyl, 7- or 8-alkyl, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines," *Zapoeozh, USSR, Farmatsevtichnii Zhurnal*, 1986, (Kiev), vol. 5, 1986, pp. 41-44.
- Clinical Trials. NCT00622284. "Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes" *ClinicalTrials.gov* (Online) No. NCT00622284, Feb. 13, 2008, p. 1-5, URL:<http://clinicaltrial.gov/ct2/show/>.
- Clinical Trials. "View of NCT00601250 on 1008-01-25: Efficacy and Safety of BI 1356 vs Placebo added to Metformin Background Therapy in Patients with Type 2 Diabetes" *Clinical Trials. Gov Archive*, [Online] Jan. 25, 2008 URL:[http://clinicaltrials.gov/archive/NCT00601250/2008\\_01\\_25](http://clinicaltrials.gov/archive/NCT00601250/2008_01_25) [retrieved on Feb. 27, 2009].
- Clinical Trials. View of NCT00730275 on Aug. 7, 2008. "A study to assess the pharmacokinetics, safety and tolerability of Sitagliptin in adolescents".
- Conarello, S.L. et al., "Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance". *PNAS*, May 27, 2003, vol. 100, No. 11, p. 6825-6830.
- Cygankiewicz, Andrzej et al., *Investigations into the Piperazine Derivatives of Dimethylxanthine*, *Acta Polon. Pharm.* [Papers of Polish Pharmacology], XXXOV, No. 5, pp. 607-612, 1977.
- Deacon, C.F. et al; "Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective," *Biochemical and Biophysical Research Communications (BBRC)* 294 (2002) 1-4.
- Deacon, C.F., et al. *Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opinion on Investigational Drugs*, 2004, September, vol. 13, No. 9, p. 1091-1102.
- DeMeester, I. et al.; "CD26, let it cut or cut it down", *Review: Immunology Today*; Aug. 1999, vol. 20, No. 8 pp. 367-375.
- Dugi, K.A. et al., "BI 1356, a novel xanthine-based DPP-IV inhibitor, exhibits high potency with a wide therapeutic window and significantly reduces postprandial glucose excursions after an oGTT". *Diabetologia*, vol. 50, No. Suppl 1, Sep. 2007, p. S367, and 43rd Annual Meeting of the European Association for the Study of Diabetes; Amsterdam, Netherlands, Sep. 18-21, 2007.
- Eckhardt Matthias et al: 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-1-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.